AAAAAA

   
Results: 1-25 | 26-50 | 51-62
Results: 1-25/62
PHARMACODYNAMIC INTERACTIONS OF ANTIBIOTICS ALONE AND IN COMBINATION
Authors: SCHENTAG JJ STRENKOSKINIX LC NIX DE FORREST A
Citation: Jj. Schentag et al., PHARMACODYNAMIC INTERACTIONS OF ANTIBIOTICS ALONE AND IN COMBINATION, Clinical infectious diseases, 27(1), 1998, pp. 40-46
GENESIS OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS (MRSA), HOW TREATMENT OF MRSA INFECTIONS WAS SELECTED FOR VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM, AND THE IMPORTANCE OF ANTIBIOTIC MANAGEMENT AND INFECTION-CONTROL
Authors: SCHENTAG JJ HYATT JM CARR JR PALADINO JA BIRMINGHAM MC ZIMMER GS CUMBO TJ
Citation: Jj. Schentag et al., GENESIS OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS (MRSA), HOW TREATMENT OF MRSA INFECTIONS WAS SELECTED FOR VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM, AND THE IMPORTANCE OF ANTIBIOTIC MANAGEMENT AND INFECTION-CONTROL, Clinical infectious diseases, 26(5), 1998, pp. 1204-1214
PANEL DISCUSSION - I - RATIONAL CONTROL OF ANTIBIOTICS IN MANAGED CARE
Authors: MEYER RD GENTRY LO KUNKEL MJ MORGENSTEIN AA POLK RE RAMIREZRONDA CH SCHENTAG JJ SYMONDS J
Citation: Rd. Meyer et al., PANEL DISCUSSION - I - RATIONAL CONTROL OF ANTIBIOTICS IN MANAGED CARE, Infectious diseases in clinical practice, 7, 1998, pp. 147-151
RISK-FACTORS FOR VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM, AND GENOTYPIC SIMILARITY BETWEEN STRAINS ISOLATED FROM PATIENTS OVER AN 18 MONTH PERIOD
Authors: HYATT JM FITZPATRICK P SCHENTAG JJ
Citation: Jm. Hyatt et al., RISK-FACTORS FOR VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM, AND GENOTYPIC SIMILARITY BETWEEN STRAINS ISOLATED FROM PATIENTS OVER AN 18 MONTH PERIOD, Infection control and hospital epidemiology, 19(9), 1998, pp. 39-39
ANTIMICROBIAL ACTIVITY OF QUINUPRISTIN-DALFOPRISTIN (RP-59500, SYNERCID(R)) TESTED AGAINST OVER 28,000 RECENT CLINICAL ISOLATES FROM 200 MEDICAL-CENTERS IN THE UNITED-STATES AND CANADA
Authors: JONES RN BALLOW CH BIEDENBACH DJ DEINHART JA SCHENTAG JJ
Citation: Rn. Jones et al., ANTIMICROBIAL ACTIVITY OF QUINUPRISTIN-DALFOPRISTIN (RP-59500, SYNERCID(R)) TESTED AGAINST OVER 28,000 RECENT CLINICAL ISOLATES FROM 200 MEDICAL-CENTERS IN THE UNITED-STATES AND CANADA, Diagnostic microbiology and infectious disease, 31(3), 1998, pp. 437-451
IN-VITRO EVALUATION OF SPARFLOXACIN ACTIVITY AND SPECTRUM AGAINST 24,940 PATHOGENS ISOLATED IN THE UNITED-STATES AND CANADA, THE FINAL ANALYSIS
Authors: JONES RN BALLOW CH SCHENTAG JJ JOHNSON DM DEINHART JA
Citation: Rn. Jones et al., IN-VITRO EVALUATION OF SPARFLOXACIN ACTIVITY AND SPECTRUM AGAINST 24,940 PATHOGENS ISOLATED IN THE UNITED-STATES AND CANADA, THE FINAL ANALYSIS, Diagnostic microbiology and infectious disease, 31(1), 1998, pp. 313-325
ANTIBIOTIC DOSING - DOES ONE SIZE FIT ALL
Authors: SCHENTAG JJ
Citation: Jj. Schentag, ANTIBIOTIC DOSING - DOES ONE SIZE FIT ALL, JAMA, the journal of the American Medical Association, 279(2), 1998, pp. 159-160
PHARMACODYNAMIC INTERACTIONS OF CIPROFLOXACIN, PIPERACILLIN, AND PIPERACILLIN TAZOBACTAM IN HEALTHY-VOLUNTEERS/
Authors: STRENKOSKINIX LC FORREST A SCHENTAG JJ NIX DE
Citation: Lc. Strenkoskinix et al., PHARMACODYNAMIC INTERACTIONS OF CIPROFLOXACIN, PIPERACILLIN, AND PIPERACILLIN TAZOBACTAM IN HEALTHY-VOLUNTEERS/, Journal of clinical pharmacology, 38(11), 1998, pp. 1063-1071
PHARMACODYNAMIC EVALUATION OF FACTORS ASSOCIATED WITH THE DEVELOPMENTOF BACTERIAL-RESISTANCE IN ACUTELY ILL PATIENTS DURING THERAPY
Authors: THOMAS JK FORREST A BHAVNANI SM HYATT JM CHENG A BALLOW CH SCHENTAG JJ
Citation: Jk. Thomas et al., PHARMACODYNAMIC EVALUATION OF FACTORS ASSOCIATED WITH THE DEVELOPMENTOF BACTERIAL-RESISTANCE IN ACUTELY ILL PATIENTS DURING THERAPY, Antimicrobial agents and chemotherapy, 42(3), 1998, pp. 521-527
PHARMACOMETRIC MODELING OF RISK-FACTORS FOR CIPROFLOXACIN RESISTANCE (CIP-R)IN PSEUDOMONAS-AERUGINOSA (PA)
Authors: HYATT JM FORREST A FEURSTEIN S SCHENTAG JJ
Citation: Jm. Hyatt et al., PHARMACOMETRIC MODELING OF RISK-FACTORS FOR CIPROFLOXACIN RESISTANCE (CIP-R)IN PSEUDOMONAS-AERUGINOSA (PA), Clinical pharmacology and therapeutics, 63(2), 1998, pp. 106-106
PHARMACOMETRIC MODELING OF RISK-FACTORS FOR IMIPENEM RESISTANCE (IMI-R) IN PSEUDOMONAS-AERUGINOSA (PA)
Authors: HYATT JM FORREST A FEURSTEIN S SCHENTAG JJ
Citation: Jm. Hyatt et al., PHARMACOMETRIC MODELING OF RISK-FACTORS FOR IMIPENEM RESISTANCE (IMI-R) IN PSEUDOMONAS-AERUGINOSA (PA), Clinical pharmacology and therapeutics, 63(2), 1998, pp. 107-107
IMPACT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR UNDERDOSING ON REHOSPITALIZATION RATES IN CONGESTIVE-HEART-FAILURE
Authors: LUZIER AB FORREST A ADELMAN M HAWARI FI SCHENTAG JJ IZZO JL
Citation: Ab. Luzier et al., IMPACT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR UNDERDOSING ON REHOSPITALIZATION RATES IN CONGESTIVE-HEART-FAILURE, The American journal of cardiology, 82(4), 1998, pp. 465-469
ASSESSING ANTIBACTERIAL PHARMACOECONOMICS IN THE INTENSIVE-CARE UNIT
Authors: BIRMINGHAM MC HASSETT JM SCHENTAG JJ PALADINO JA
Citation: Mc. Birmingham et al., ASSESSING ANTIBACTERIAL PHARMACOECONOMICS IN THE INTENSIVE-CARE UNIT, PharmacoEconomics, 12(6), 1997, pp. 637-647
ASSESSMENT OF THE ENZYMURIA RESULTING FROM GENTAMICIN ALONE AND COMBINATIONS OF GENTAMICIN WITH VARIOUS BETA-LACTAM ANTIBIOTICS
Authors: NIX DE THOMAS JK SYMONDS WT SPIVEY JM WILTON JH GAGLIARDI NC SCHENTAG JJ
Citation: De. Nix et al., ASSESSMENT OF THE ENZYMURIA RESULTING FROM GENTAMICIN ALONE AND COMBINATIONS OF GENTAMICIN WITH VARIOUS BETA-LACTAM ANTIBIOTICS, The Annals of pharmacotherapy, 31(6), 1997, pp. 696-703
CHANGING THE INFECTION-CONTROL PARADIGM FROM OFF-LINE TO REAL-TIME - THE EXPERIENCE AT MILLARD-FILLMORE-HEALTH-SYSTEM
Authors: CARR JR FITZPATRICK P IZZO JL CUMBO TJ BIRMINGHAM MC ADELMAN MH PALADINO JA HANSON SC SCHENTAG JJ
Citation: Jr. Carr et al., CHANGING THE INFECTION-CONTROL PARADIGM FROM OFF-LINE TO REAL-TIME - THE EXPERIENCE AT MILLARD-FILLMORE-HEALTH-SYSTEM, Infection control and hospital epidemiology, 18(4), 1997, pp. 255-259
COMPARATIVE IN-VITRO ASSESSMENT OF SPARFLOXACIN ACTIVITY AND SPECTRUMUSING RESULTS FROM OVER 14,000 PATHOGENS ISOLATED AT 190 MEDICAL-CENTERS IN THE USA
Authors: BALLOW CH JONES RN JOHNSON DM DEINHART JA SCHENTAG JJ TRITSCH M ELLIS S BURGER J COLE E VENEZIA R GEORGE M WOLF D SLIFKIN M DEPALMA J RUDRIK J SULLIVAN K LEWIS G DOOLEY G SAWICKI R DESIDERIO D LOUMA R MOTYL M RUFFIN L TORRESAN J DUNAWAY G KECK G TRUITT L BRECHER S VANENK R WHELEN C FADER R WHISLER G JENKINS S THACKER D DAMATO R BUCK R BUESCHER S LAMBERT K TRISTRAM D KEHL S LAWSON C WASHINGTON J ROBERTSON K BEALL A PADGETT L RAHMAN L RIDDLE G DELLALATTA P MARCON M NORTHERN I MAGALLON B KOCKA F RHOADS S MORTON V GRAVES J RYBAK M BROWN W SOSNOWSKI K KHALIFE W GIGER O GIPSON R PARK C HERNANDEZ S OLDING T TAYLOR D MITCHELL M HOGAN B SATHER P HORNER A ROGERS P SAUTTER R HOBAN D MARTENS M APPELBAUM P LATINO J POON P HOUK J WALSH W CONDOTTI P REYNOLDS J HERRING A MADISON B FREUNZILICH L FUSCO J TURNER N ISENBERG H SWEENEY L GAUTHIERS S DAY T WRIGHT L ALBERT S AIROLDI T TAY T TAUBENHEIM D WILLIAMS C SELLEN T DAVENPORT M DOWNING L DENYS G AHMED M DAVIS S LAND G BOYLE J TALLENT S SHARP S PENDOWSKI C KLEIN R NEWTON J CZEREPUSZKO D STEINKRAUS G PUTTLITZ D WASILAUSKAS B PHILLIPS H VENTURELLA J OCONNELL A COLLINS C IMBORIBOON H PANKEY G VORA R BACHMANN N SOUTHERN P FAIRBANKS L HOWARD J LEBAR W THOMAS E VELAZCO D WEINSTEIN M VELLETRI K BETZ I HAYDEN M HOFFMAN M WAEFORD F GOODWIN J THACKERAY A TOMLINSON R CUCCHIARA F HUDAK P JONES D SCHECHTERLY C STELLMACH J NORDLOF V MORTENSEN J DICKSON J GISH N CAVALIERI S KENYON V RAWLING R MATTICS C STROZEWSKI C ALIKAHN M KROH H NGO T OAKES G BAEKERHOVDE L MARKOVIC M TAMME L GORDON M HAGEAGE G FILE T FORBES B HUBER T CHESLEY D HAMWAY S WAITES K MONAHAN J JONES R OVERMAN S SNYDER J SCHWALBE R HUMPHRIES J OVERTURF G WANGER A CARROLL K FRITSCHE T WELCH D FISHER C DAILY J GRENDISA S REIMER L GAYDOS M SEWELL D JENSEN B PFLEGER S SEIPLE J JOVELLANOS P VANHORN K CARRO A FULLER D BOSTIC G
Citation: Ch. Ballow et al., COMPARATIVE IN-VITRO ASSESSMENT OF SPARFLOXACIN ACTIVITY AND SPECTRUMUSING RESULTS FROM OVER 14,000 PATHOGENS ISOLATED AT 190 MEDICAL-CENTERS IN THE USA, Diagnostic microbiology and infectious disease, 29(3), 1997, pp. 173-186
PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL GREPAFLOXACIN IN PATIENTS WITH ACUTE BACTERIAL EXACERBATIONS OF CHRONIC-BRONCHITIS
Authors: FORREST A CHODOSH S AMANTEA MA COLLINS DA SCHENTAG JJ
Citation: A. Forrest et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL GREPAFLOXACIN IN PATIENTS WITH ACUTE BACTERIAL EXACERBATIONS OF CHRONIC-BRONCHITIS, Journal of antimicrobial chemotherapy, 40, 1997, pp. 45-57
MODELING THE RESPONSE OF PNEUMONIA TO ANTIMICROBIAL THERAPY
Authors: HYATT JM LUZIER AB FORREST A BALLOW CH SCHENTAG JJ
Citation: Jm. Hyatt et al., MODELING THE RESPONSE OF PNEUMONIA TO ANTIMICROBIAL THERAPY, Antimicrobial agents and chemotherapy, 41(6), 1997, pp. 1269-1274
PHARMACODYNAMIC MODELING OF THE IN-VIVO INTERACTION BETWEEN CEFOTAXIME AND OFLOXACIN BY USING SERUM ULTRAFILTRATE INHIBITORY TITERS
Authors: NIX DE WILTON JH HYATT J THOMAS J STRENKOSKINIX LC FORREST A SCHENTAG JJ
Citation: De. Nix et al., PHARMACODYNAMIC MODELING OF THE IN-VIVO INTERACTION BETWEEN CEFOTAXIME AND OFLOXACIN BY USING SERUM ULTRAFILTRATE INHIBITORY TITERS, Antimicrobial agents and chemotherapy, 41(5), 1997, pp. 1108-1114
ANTIBIOTIC SELECTION AND DOSING FOR THE TREATMENT OF ACUTE EXACERBATIONS OF COPD
Authors: SCHENTAG JJ TILLOTSON GS
Citation: Jj. Schentag et Gs. Tillotson, ANTIBIOTIC SELECTION AND DOSING FOR THE TREATMENT OF ACUTE EXACERBATIONS OF COPD, Chest, 112(6), 1997, pp. 314-319
PHARMACOMETRIC MODELING OF RISK-FACTORS FOR MRSA
Authors: HYATT JM FORREST A FEUERSTEIN S SCHENTAG JJ
Citation: Jm. Hyatt et al., PHARMACOMETRIC MODELING OF RISK-FACTORS FOR MRSA, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 82-82
A PHARMACOMETRIC MODEL FOR FACTORS IN THE DEVELOPMENT OF BACTERIAL-RESISTANCE IN ACUTELY ILL PATIENTS
Authors: THOMAS JK HYATT JM FORREST A SCHENTAG JJ
Citation: Jk. Thomas et al., A PHARMACOMETRIC MODEL FOR FACTORS IN THE DEVELOPMENT OF BACTERIAL-RESISTANCE IN ACUTELY ILL PATIENTS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 87-87
THE ECONOMIC-POTENTIAL OF DUAL INDIVIDUALIZATION METHODOLOGIES
Authors: PALADINO JA ZIMMER GS SCHENTAG JJ
Citation: Ja. Paladino et al., THE ECONOMIC-POTENTIAL OF DUAL INDIVIDUALIZATION METHODOLOGIES, PharmacoEconomics, 10(6), 1996, pp. 539-545
PERFORMANCE OF THE FRACTIONAL MAXIMAL EFFECT METHOD - COMPARATIVE INTERACTION STUDIES OF CIPROFLOXACIN AND PROTEIN-SYNTHESIS INHIBITORS
Authors: LI RC NIX DE SCHENTAG JJ
Citation: Rc. Li et al., PERFORMANCE OF THE FRACTIONAL MAXIMAL EFFECT METHOD - COMPARATIVE INTERACTION STUDIES OF CIPROFLOXACIN AND PROTEIN-SYNTHESIS INHIBITORS, Journal of chemotherapy, 8(1), 1996, pp. 25-32
BENCHMARK ANALYSIS OF STRATEGIES HOSPITALS USE TO CONTROL ANTIMICROBIAL EXPENDITURES
Authors: RIFENBURG RP PALADINO JA HANSON SC TUTTLE JA SCHENTAG JJ
Citation: Rp. Rifenburg et al., BENCHMARK ANALYSIS OF STRATEGIES HOSPITALS USE TO CONTROL ANTIMICROBIAL EXPENDITURES, American journal of health-system pharmacy, 53(17), 1996, pp. 2054-2062
Risultati: 1-25 | 26-50 | 51-62